Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Sanford Burnham Prebys Medical Discovery Institute |
| Country | United States |
| Start Date | Sep 09, 2024 |
| End Date | Aug 31, 2029 |
| Duration | 1,817 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10935867 |
PROJECT SUMMARY – PROJECT 3 The incidence of NASH-driven HCC is expected to increase worldwide due to its association with the obesity and type-2 diabetes epidemic. Chronic ER stress and overnutrition synergize to drive NASH-HCC and metabolic stress affects ER and mitochondrial function through mitochondria-associated membranes (MAM). SAB
(SH3BP5) and STARD1, two mitochondrial-resident proteins induced by ER stress, contribute to ER- mitochondria crosstalk in acute liver injury. STARD1 transfers cholesterol to the mitochondrial inner membrane for metabolism to bile acids (BAs) in the alternative (acidic) pathway. SAB acts as a docking protein required for
sustained p-JNK activation through mitochondrial dysfunction and an amplification of reactive oxygen species generation. Although basal levels of STARD1 and SAB are low, their expression increases in human NASH- HCC samples. We hypothesize that SAB and STARD1 act as complementary partners and downstream
mediators of the NRF2/ATF6/FBP-1 loss network to induce mitochondrial dysfunction and metabolic reprogramming through the switch of BAs synthesis from the classic to the alternative pathway. Specific aims: Aim 1. How does STARD1-SAB/JNK promote NASH-driven HCC? We hypothesize that STARD1-SAB/JNK alters BA homeostasis leading to HCC development. 1.1. How does BAs generated through the alternative
pathway lead to loss of FBP-1? 1.2 What is the effect of STARD1-SAB-JNK ablation on BAs and FBP-1 expression in human HCC PDXs/spheroids? 1.3 Determination of the tumorigenic potential of HCC cell lines from MUP- uPA/NRFAct-Hep mice. Aim 2. How does STARD1-SAB/JNK axis alter the lipid composition of
MAMs/Mitochondria and cause ER stress to promote NASH-driven HCC? We hypothesize that STARD1 regulates mitochondrial cholesterol content and SAB/JNK changes MAM lipid composition via MFN-2 degradation, leading to metabolic reprogramming for HCC. 2.1 Determination of the lipidome of MAMs/Mitochondria from MUP-uPA/NRF2Act-Hep-derived HCC and the role of STARD1-SAB/JNK knockdown.
2.2 Analyze MAM/mitochondrial lipid composition in human HCC PDXs/spheroids. 2.3 How does ER stress induce STARD1-SAB expression to promote HCC? Aim 3. How does STARD1-SAB/JNK metabolic reprogramming lead to NASH-driven HCC? We postulate that STARD1-induced cholesterol trafficking and SAB-mediated JNK activation suppress oxidative phosphorylation, increase glycolysis and impair mitophagy to
favor HCC development. 3.1 Determination of mitochondrial function, glycolysis and mitophagy in MUP- uPA/NRFAct-ΔHep mice. 3.2 Examination of mitochondrial function and glycolysis of HCC cell lines and human PDXs/spheroids. 3.3 Impact of STARD1-SAB/JNK in stabilization of HIF-1. Thus, it is anticipated that the
integration of our work with Projects 1 and 2 and Cores 1 and 2 will advance our understanding of HCC pathogenesis and lead to new therapeutic approaches.
Sanford Burnham Prebys Medical Discovery Institute
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant